Skip to content

Oxidoreductive Balance and Lysosomal Activity in Cancer Patients.

Oxidative Stress and Inflammatory Processes in Selected Neoplasms in the Group of Oncological Patients Examined With the FDG PET/CT Method.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03470857
Enrollment
83
Registered
2018-03-20
Start date
2017-06-19
Completion date
2021-06-30
Last updated
2022-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antioxidants, Inflammation, Lipid Peroxidation, Lysosome Alteration, Neoplasms, Oxidative Stress

Keywords

Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Cancer, Superooxide Dismutase, Catalase, Glutathione Peroxidase, Malondialdehyde, Conjugated Dienes, Acid Phosphatase, Cathepsin D, Alpha-1-Antitrypsin, Arylsulfatase, 8-iso-Prostaglandin F2alpha, 4-Hydroxynonenal, Total Antioxidant Capacity, Vitamin A, Vitamin E

Brief summary

The research aims to determine the parameters of oxidative stress and inflammatory processes and compare these parameters with the image obtained using positron emission tomography (PET) with 2-deoxy-2-\[fluorine-18\]fluoro- D-glucose (18F-FDG) integrated with computed tomography (CT) in the group of oncological patients.

Detailed description

FDG PET/CT is very sensitive imaging tool for the detection of neoplasms. Neoplasm tissue is characterized by a much higher level of metabolism than healthy tissues, therefore a 95% cases of use the method regard oncology. Fluorodeoxyglucose (FDG) is absorbed by patients' organism as glucose but it does not undergo metabolism. The increased degree of FDG accumulation in tissue means its higher metabolic activity. FDG accumulates in the tumor tissue and radiates enabling its detection but the substance has not been shown to be harmful to patient at doses used in the diagnostics. Tumor formation is a multi-stage process in which the phases of initiation, promotion and progression are distinguished. Neoplastic transformation of healthy cells is associated with disturbances of the cell cycle caused by mutations of proto-oncogenes (activation of cell division) and/or suppressor genes (blocking cell division) and mutator genes (protecting the DNA against damage or its repairing) under the influence of various factors. Increasing data indicate that one of the most important factors initiating neoplasm are reactive oxygen species (ROS) and oxidative stress. Mechanisms responsible for induction of oxidative stress in cancer cells are not fully explained. It is known that they are closely related to inflammation, as well as intense cellular metabolism associated with continuous proliferation, mutations in the genetic material and dysfunctions in the mitochondrial respiratory chain. In this study a number of markers of oxidative stress and inflammation are planned to be determined including: the activities of antioxidant and lysosomal enzymes, as well as concentrations of lipid peroxidation products and low molecular weight antioxidants. The PET/CT imaging will be performed as part of standard medical procedures related to the diagnosis and monitoring of cancer diseases at the Oncology Center in Bydgoszcz, Poland.

Interventions

DIAGNOSTIC_TESTPatients

The FDG PET/CT imaging will be performed as part of typical medical procedures related to the diagnosis and monitoring of cancers at the Oncology Center in Bydgoszcz, Poland

Sponsors

Nicolaus Copernicus University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

\- sign informed consent form for participation in the study

Exclusion criteria

* other diseases, * bad feeling of the studied individual on the day of the study, * the participants will not be minor and incapacitated persons, soldiers, prisoners and persons dependent in any way from the investigators.

Design outcomes

Primary

MeasureTime frameDescription
Vitamins A and E1 day (Single measurement)Low molecular weight antioxidants
Superoxide Dismutase1 day (Single measurement)Antioxidant enzyme
Catalase1 day (Single measurement)Antioxidant enzyme
Glutathione Peroxidase1 day (Single measurement)Antioxidant enzyme
Thiobarbituric acid reactive substances (Malondialdehyde)1 day (Single measurement)Secondary lipid peroxidation product
Conjugated Dienes1 day (Single measurement)Primary lipid peroxidation product
8-iso-Prostaglandin F2alpha1 day (Single measurement)Secondary lipid peroxidation product
4-Hydroxynonenal1 day (Single measurement)Secondary lipid peroxidation product
Total Antioxidant Capacity1 day (Single measurement)Total antioxidant potential of blood serum in the participant
Acid Phosphatase1 day (Single measurement)Lysosomal enzyme
Cathepsin D1 day (Single measurement)Lysosomal enzyme
Arylsulfatase1 day (Single measurement)Lysosomal enzyme
Alpha-1-Antitrypsin1 day (Single measurement)Serine protease inhibitor

Secondary

MeasureTime frameDescription
FDG PET/CT scanning1 day (Single measurement)Positron emission tomography with 2-deoxy-2-\[fluorine-18\]fluoro- D-glucose integrated with computed tomography

Countries

Poland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026